8 results about "Lacidipine" patented technology

The invention relates to an application of a dihydropyridine compound or a salt thereof in preparation of a medicine for preventing and / or treating HPV infection, and belongs to the technical field of medicines and medicinal preparations. The invention provides application of a dihydropyridine compound or a salt thereof in preparation of a medicine for preventing and / or treating HPV (human papillomavirus) infection. The dihydropyridine compound is selected from one or more of nifedipine, amlodipine, lercanidipine, nimodipine, nitrendipine, nisoldipine, felodipine, benidipine, lacidipine and azelnidipine. According to the scheme, the application of the dihydropyridine compound or the salt thereof in prevention and / or treatment of HPV is reported for the first time, and an in-vitro cell experiment is carried out through azelnidipine in the dihydropyridine compound; furthermore, the inhibition effect on the HPV virus is verified through mouse intradermal vaccination virus model drug delivery and mouse vaginal vaccination virus model drug delivery.

The invention discloses a lacidipine film-controlled sustained-release pellet capsule and a preparation method thereof, relates to the technical field of medicines, and aims to solve the problem of release reduction caused by film aging of a lacidipine film-controlled sustained-release pellet prepared by an aqueous dispersion coating. The preparation method comprises the following steps: respectively weighing a lacidipine bulk drug, a polymer carrier material and a plasticizer according to a prescription amount, grinding and uniformly mixing to prepare the lacidipine solid dispersion. A sustained-release coating film of the pellet capsule contains Eurdragit RL30D, a plasticizer triethyl citrate and an anti-sticking agent talcum powder, and a pellet core contains croscarmellose sodium and an excipient. According to the lacidipine solid dispersion solid preparation provided by the invention, lacidipine exists in the carrier material in a microcrystalline state, an amorphous state, a colloidal dispersion state or a molecular dispersion state, so that the lacidipine solid dispersion solid preparation has high dispersity, the dissolution speed of a medicine is accelerated, the absorption of the medicine can be promoted, and the bioavailability is improved.

The invention discloses a rapid detection method for lacidipine and fluvoxamine in accident site serum, and relates to the technical field of trace drug detection in biological samples. The method comprises the following steps: preparing a surface enhanced Raman spectrum substrate with gold nanoparticles loaded on amino modified MIL-101 (Cr), and combining sample extraction, oscillation adsorption, centrifugal separation and Raman spectrum detection: mixing a sample solution and the substrate according to a volume ratio of 1: 3, carrying out oscillation adsorption at 35 DEG C for 30-40 minutes, then carrying out centrifugal collection, collecting a spectrum signal by adopting a 785nm laser, and calculating the Raman spectrum based on the spectrum signal. And the qualitative analysis of the target drug is realized by identifying the characteristic peaks of 1632 cm <-1 > + / -2 cm <-1 > and 1060 cm <-1 > + / -2 cm <-1 >. The method has the characteristics of rapidness, high efficiency, no need of complex pretreatment and high sensitivity, is suitable for rapid detection of lacidipine and fluvoxamine in a serum sample on an accident site, and provides technical support for clinical first aid and judicial expertise.

The invention relates to a hypertension implant rod and a preparation method thereof, and relates to the technical field of hypertension implant rods, the hypertension implant rod comprises a quick release layer, a slow release layer and a long-acting regulation and control layer from outside to inside, the quick release layer comprises, by mass, 60-70% of bacterial cellulose (BC), 15-25% of polydopamine (PDA), 3-8% of ciprofloxacin, 3-8% of protamine and 4-6% of indapamide, the slow release layer comprises, by mass, 20-30% of a long-acting regulation and control layer, and the long-acting regulation and control layer comprises, by mass, 20-30% of a slow release layer and 20-30% of a long-acting regulation and control layer. The sustained release layer is prepared from 55 to 65 percent of polylactic acid-glycolic acid copolymer, 20 to 30 percent of cross-linked gelatin, 8 to 12 percent of lacidipine and 4 to 6 percent of spirolactone, and the long-acting regulation and control layer is prepared from 65 to 75 percent of L-polylactic acid, 20 to 30 percent of beta-glycine crystal, 3 to 5 percent of silk fibroin (SF), 0.5 to 1.0 percent of calcitonin gene related peptide CGRP and 0.1 to 0.3 percent of neuropeptide Y. The hypertension implant rod can be matched with various treatment cycles through gradient degradation, realizes'on-demand treatment ', is high in biocompatibility, is suitable for subcutaneous implantation, and is convenient and safe to operate.

The application relates to application of a dihydropyridine compound or a salt thereof in preparation of a medicine for preventing and / or treating HPV infection, and belongs to the technical field of medicines and pharmaceutical preparations. The application provides application of the dihydropyridine compound or the salt thereof in preparation of the medicine for preventing and / or treating HPV infection, wherein the dihydropyridine compound is selected from one or more of nifedipine, amlodipine, lercanidipine, nimodipine, nitrendipine, nisoldipine, felodipine, benidipine, lacidipine and azelnidipine. The application scheme first reports the application of the dihydropyridine compound or the salt thereof in prevention and / or treatment of HPV, and in-vitro cell experiments are carried out through azelnidipine in the dihydropyridine compound, and further, the inhibiting effect of the dihydropyridine compound on HPV virus is verified through medicine administration of a mouse intradermal virus inoculation model and medicine administration of a mouse vaginal virus inoculation model.

The invention provides application of lacidipine in preparation of IDO inhibitors and / or antitumor drugs, and belongs to the technical field of chemical drugs. Research finds that lacidipine is an IDO inhibitor with double functions, can inhibit expression of IDO in tumors and can inhibit enzyme activity; the lacidipine plays a good anti-tumor role by inhibiting the difunction of IDO (indoleamine-2, 3-dioxygenase). The lacidipine can promote effector T cells, inhibit tumor infiltration and functions of Tregs cells and inhibit further metastasis of tumors. The lacidipine can also be combined with other anti-tumor drugs to play a synergistic anti-tumor effect. The invention also provides a new treatment strategy for enhancing antitumor immune response by clinically applying antihypertensive drugs.

The invention relates to a preparation method of a lacidipine intermediate compound. A compound II and a compound III react in the presence of organic alkali. The method has the advantages of simple and mild reaction conditions, high yield, few side reactions and cheap and easily available raw materials, and is suitable for industrial production.

The invention relates to the field of medical technology, and discloses a lacidipine tablet and a preparation method thereof. The weight ratio of raw materials of the lacidipine tablet is: 2%-4% lacidipine; 1%-1.9% surfactant; 8%-10% cellulose polymer; 1.1%-1.6% acrylic resin polymer material; 0.8%-1.2% triglyceride; 1.3%-1.7% carbomer; and the remainder is lactose. The raw material formula is weighed, the prepared raw materials are melt-mixed in sequence, the mixture is added into an extruder, and the process parameters of the extruder are adjusted to finally obtain an initial lacidipine tablet, and then the initial lacidipine tablet is further subjected to a devolatilization operation, and a cellulose polymer is used for coating treatment. After the coating is completed, the lacidipine tablet is prepared, and the lacidipine tablet is subjected to evaluation tests of dissolution rate and cumulative dissolution rate. Finally, according to the test results, the formula and process parameters are adjusted. The preparation according to the above raw material formula combined with a hot melt extrusion process can effectively overcome the problem of low dissolution rate and low cumulative dissolution rate in the existing preparation method.